Emerging data suggest Retatru tide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to provide a significant step forward for weight treatment. Preliminary human trials have demonstrated impressive reductions in body tissue, potentially